• Facebook
  • Twitter


4891 東証グロース(医薬品)




(公開日 2022.11.25)


TMR(4891 TSE Growth)

English Summary (PDF)

+English Summary on This Page

Drug discovery bioventure originated by Tokyo University of Agriculture and Technology

Drug Discovery Bioventure
TMS was founded in 2005 for the purpose of commercializing the pharmaceutical seeds of the Department of Fermentation Science and Technology (Professor Keiji Hasumi) of Tokyo University of Agriculture and Technology. It is a drug discovery-based bioventure whose objective is the development of drugs for the global pharmaceutical market.

Drug Development Using SMTP Compounds
Currently, the company is developing pharmaceuticals that utilize the anti-inflammatory effects of staplabin, a compound produced by Stachybotrys microspora, a type of black mold, and SMTP (stachybotrys microspora triprenyl phenol) compounds, which consist of about 60 derivatives, and the prothrombolytic effects of certain SMTP compounds.

Development Pipeline
The current pipeline consists of two compounds, TMS-007 and TMS-008, with TMS-009 as a backup compound for TMS-008.

TMS-007 has anti-inflammatory and prothrombolytic effects and is being developed for the treatment of acute ischemic strokes. It is superior in terms of efficacy and safety to existing drugs, as evidenced by its acting only at the site of a blood clot and not having intracranial hemorrhage as a side effect. The phase 2a clinical trial in Japan was completed in August 2021. In May 2021, the product was licensed out to Biogen, who will be responsible for its future development and marketing. The company could recognize up to $335 million in milestone revenue on TMS-007, as well as post-launch royalties from the high single-digits to 10% to 15% of drug net sales until the expiration of development patent rights or six years after the launch of sales, whichever comes later.

TMS-008 is presently in the preclinical stage for the indications of acute kidney injury and cancer cachexia, and is aiming to enter clinical trials for acute kidney injury in fiscal year ending February 2024. The company intends to license the drug following confirmation of its efficacy in humans in the first-phase clinical trials.



現在は、黒カビの一種であるスタキボトリス・ミクロスポラ(Stachybotrys Microspora)が産生する化合物(Staplabin)及び、その誘導体約60種類からなるSMTP(Stachybotrys Microspora Triprenyl Phenol)化合物が持つ抗炎症作用及び、一部のSMTP化合物が持つ血栓溶解効果を利用した医薬品の開発を進めている。

SMTP化合物による抗炎症作用はsEH (可溶性エポキシドハイドロラーゼ)の阻害により得られる。sEHは、ヒトが体内に持つ酵素の一つで、二つの作用を有すると考えられている。

一つ目は、エポキシド構造の化合物を加水分解する作用(EH活性)で、具体的には炎症を抑制する効果がある生理活性脂質エポキシエイコサトリエン酸(EETs:Epoxyeicosatrienoic Acid)を加水分解によりジヒドロキシエイコサトリエン酸(DHETs:Dihydroxyeicosatrienoic Acid)に変換する作用である。このため、sEHを阻害することで、抗炎症作用を持つEETsの減少を抑えることができる。

もう一つは、脱リン酸化作用(Phos活性)で、 sEHの脱リン酸化作用の詳細はまだほとんど解明されていないが、同社が東京農工大学等の共同研究で解明に取り組んでおり、sEH阻害による抗炎症作用の中核を担う作用であることが分かってきている。








  • Google play
  • App Store